Core Insights - Structure Therapeutics is advancing its oral small molecule therapeutics for metabolic diseases, particularly obesity, with significant clinical milestones expected by the end of 2025 [1][2][5] Clinical Development - The Phase 2b ACCESS and ACCESS II studies for aleniglipron (GSBR-1290), an oral small molecule GLP-1 receptor agonist, are fully enrolled and on track for topline data readout by year-end 2025 [5] - ACCESS study enrolled approximately 220 adults with obesity or overweight with weight-related comorbidities, evaluating doses up to 120 mg of aleniglipron [5] - ACCESS II study enrolled approximately 80 adults, evaluating higher doses of aleniglipron (180 mg and 240 mg) [5] - The Phase 1 study for ACCG-2671, an oral small molecule amylin receptor agonist, is anticipated to initiate by year-end 2025 [1][2][5] Financial Position - As of March 31, 2025, the company reported cash, cash equivalents, and short-term investments totaling $836.9 million, expected to fund operations through at least 2027 [7] - Research and Development (R&D) expenses for Q1 2025 were $42.9 million, up from $20.7 million in Q1 2024, primarily due to increased clinical trial costs and personnel expenses [8] - General and Administrative (G&A) expenses for Q1 2025 were $13.4 million, compared to $11.3 million in Q1 2024, driven by personnel-related expenses [9] - The net loss for Q1 2025 was $46.8 million, compared to a net loss of $26.0 million in Q1 2024 [10] Pipeline and Future Directions - Structure Therapeutics is exploring additional indications for GLP-1 receptor agonists beyond obesity, including Parkinson's disease, with preclinical data to be presented at the ADA 85 Scientific Sessions in June 2025 [5] - The company is also developing GIPR and GCGR selective agonists and antagonists, as well as evaluating ANPA-0073, a Phase 2 ready biased APJR agonist for potential muscle-sparing weight loss [5][6]